The California Department of Public Health has announced participation in a pilot project with St. Joseph Health to better understand cancer trends in California.
A collaboration between a leading healthcare system and a state’s department of public health could only be for the better, and the state of California hopes it’s true. The California Department of Public Health (CDPH) has announced that since January 2014, the Department has participated in a historic pilot project with St. Joseph Health to better understand cancer trends in California. This premise of the partnership—the first in the United States—is that structured pathology cancer data from the health system will be directly shared with the California Cancer Registry (CCR).
“Every second we save in sharing data gives researchers more time to spend on curing cancer,” said Dr Karen Smith, director of CDPH, in a statement. “This partnership is another way in which the California Department of Public Health works with the private sector and health care systems to optimize the health and well-being of the people in California.”
CCR is a population-based cancer surveillance system that collects information on all cancers diagnosed in the state of California, and the data is analyzed to develop strategies and policies on prevention, treatment, and control. Additionally, decisions on early detection and education programs stem out of this data. Now, with this collaboration, CCR can perform real-time surveillance, which has the potential to improve patient treatment and outcomes.
According to a press release by CDPH, 10 hospitals within the St. Joseph Health system are now sending data directly to CCR, with other healthcare facilities expected to participate in the future. The current pilot project is a collaboration between CDPH, St Joseph Health, the technology company mTuitive, and the College of American Pathologists (CAP). The pathology data-capture with this project will be a big transformation from the text-heavy narrative of a typical pathology report in the patient’s electronic medical record. St. Joseph Health is using CAP eFRM, a reporting module developed jointly by CAP and mTuitive, to collect and transfer cancer diagnostic data to CCR.
An expanding project, mTuitive is seeking additional laboratories to collaborate with in this project.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
2 Clarke Drive
Cranbury, NJ 08512